Xilio Therapeutics names Yariv Houvras chief medical officer

XLO•2026-09-28

Xilio Therapeutics named Yariv J. Houvras chief medical officer on Sept. 28, 2026.

1. Houvras joins Xilio

Houvras previously led clinical and translational development at Tubulis, overseeing antibody-drug conjugate programs through its acquisition by Gilead Sciences. Earlier, he was a senior medical director at Regeneron, supporting linvoseltamab development from first-in-human studies to U.S. and EU approvals.

Xilio Therapeutics names Yariv Houvras chief medical officer

1. Houvras joins Xilio

Related News

Corporación América Airports says Argentina shifts passenger tariffs to U.S. dollars, lifts domestic fee to USD 9 by 2027

First Mid Ag Services says professionally managed Illinois farmland rises 156% since 2016 survey

Lightspeed Commerce coverage starts with equalweight rating and $9.5 target

Silicon Valley Acquisition amends EigenQ deal to swap certain company warrants for PubCo warrants at closing

Volato Alignment Engine signs USD 1.17 billion AI infrastructure orders with large AI customer